Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM6OZQV)

Drug Name

Daclizumab Drug Info

Synonyms

DAC HYP; Daclizumab HYP; Daclizumab High Yield Process; Daclizumab (subcutaneous, multiple sclerosis); Daclizumab (subcutaneous, multiple sclerosis), Abbott/Biogen Idec

Indication

Disease Entry	ICD 11	Status	REF
Aplastic anemia	3A70	Approved	[1]
Kidney transplant rejection	NE84	Approved	[2]
Multiple sclerosis	8A40	Approved	[3]

Cross-matching ID

TTD Drug ID: DM6OZQV

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-2 (IL2)	TTF89GD	IL2_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Interleukin-2 (IL2)	DTT	IL2	0.848	4.548	3.548	4.053

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Aplastic anemia

ICD Disease Classification

3A70

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin-2 (IL2)	DTT	IL2	7.64E-01	1.04E-02	0.07

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Recent developments in drug therapy for aplastic anemia. Ann Pharmacother. 2014 Nov;48(11):1469-78.
2	Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007 Dec 20;357(25):2562-75.
3	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.